文献速递乳腺外科

SINODAR-ONE 亚组分析:全乳切除伴 1–2 枚前哨淋巴结转移者或可豁免腋窝清扫

Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
PubMed 文献 · Br J Surg · 2023-01-01

该研究为 SINODAR-ONE 随机临床试验的预设亚组分析,纳入 218 例接受全乳切除的 T1-2 期乳腺癌且前哨淋巴结转移不超过 2 枚的患者,随机分为腋窝淋巴结清扫组(111 例)与前哨淋巴结活检 alone 组(107 例)。中位随访 33.0 个月,两组的 5 年总生存率和无复发生存率均无显著差异,且未观察到腋窝淋巴结复发。

要点

  • 全乳切除的 T1-2 期乳腺癌伴 1–2 枚前哨淋巴结宏转移者,仅行前哨淋巴结活检未增加复发风险。
  • 中位随访 33.0 个月时,两组 5 年总生存率分别为 97.8% 与 98.7%(P=0.597)。
  • 两组 5 年无复发生存率分别为 95.7% 与 94.1%(P=0.821),均未出现腋窝淋巴结复发。

核心结论

  • 在接受全乳切除的 T1-2 期乳腺癌且 1–2 枚前哨淋巴结宏转移的患者中,仅行前哨淋巴结活检的总生存率和无复发生存率不劣于腋窝淋巴结清扫。

研究设计与样本

  • SINODAR-ONE 多中心随机临床试验的亚组分析,纳入 218 例接受全乳切除的 T1-2 期乳腺癌且前哨淋巴结转移不超过 2 枚的患者,随机分为腋窝淋巴结清扫组(111 例)和前哨淋巴结活检 alone 组(107 例)。

主要发现

  • 中位随访 33.0 个月,腋窝淋巴结清扫组死亡 2 例,前哨淋巴结活检 alone 组死亡 1 例;两组各发生 5 例复发,均未观察到腋窝淋巴结复发。
  • 腋窝淋巴结清扫组与前哨淋巴结活检 alone 组的 5 年总生存率分别为 97.8% 与 98.7%(P=0.597)。
  • 腋窝淋巴结清扫组与前哨淋巴结活检 alone 组的 5 年无复发生存率分别为 95.7% 与 94.1%(P=0.821)。

临床怎么用

  • 对于接受全乳切除的 T1-2 期乳腺癌且前哨淋巴结转移 1–2 枚的患者,可考虑仅行前哨淋巴结活检而豁免腋窝淋巴结清扫。

局限性

  • 该分析为 SINODAR-ONE 试验的亚组分析,样本量有限(218 例),中位随访时间仅 33.0 个月。
  • 为强化试验结论,研究者已重新开放全乳切除患者的入组,作为单臂实验性研究(注册号 NCT05160324)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The initial results of the SINODAR-ONE randomized clinical trial reported that patients with T1-2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with breast-conserving surgery, sentinel lymph node biopsy only, and adjuvant therapy did not present worse 3-year survival, regional recurrence, or distant recurrence rates compared with those treated with axillary lymph node dissection. To extend the recommendation of axillary lymph node dissection omission even in patients treated with mastectomy, a sub-analysis of the SINODAR-ONE trial is presented here. METHODS: Patients with T1-2 breast cancer and no more than two metastatic sentinel lymph nodes undergoing mastectomy were analysed. After sentinel lymph node biopsy, patients were randomly assigned to receive either axillary lymph node dissection followed by adjuvant treatment (standard arm) or adjuvant treatment alone (experimental arm). The primary endpoint was overall survival. The secondary endpoint was recurrence-free survival. RESULTS: A total of 218 patients were treated with mastectomy; 111 were randomly assigned to the axillary lymph node dissection group and 107 to the sentinel lymph node biopsy-only group. At a median follow-up of 33.0 months, there were three deaths (two deaths in the axillary lymph node dissection group and one death in the sentinel lymph node biopsy-only group). There were five recurrences in each treatment arm. No axillary lymph node recurrence was observed. The 5-year overall survival rates were 97.8 and 98.7 per cent in the axillary lymph node dissection treatment arm and the sentinel lymph node biopsy-only treatment arm, respectively (P = 0.597). The 5-year recurrence-free survival rates were 95.7 and 94.1 per cent in the axillary lymph node dissection treatment arm and the sentinel lymph node biopsy treatment arm, respectively (P = 0.821). CONCLUSION: In patients with T1-2 breast cancer and one to two macrometastatic sentinel lymph nodes treated with mastectomy, the overall survival and recurrence-free survival rates of patients treated with sentinel lymph node biopsy only were not inferior to those treated with axillary lymph node dissection. To strengthen the conclusion of the trial, the enrolment of patients treated with mastectomy was reopened as a single-arm experimental study. REGISTRATION NUMBER: NCT05160324 (http://www.clinicaltrials.gov).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Tinterri C, Canavese G, Gatzemeier W, et al. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. Br J Surg. 2023. PMID: 37471574. doi:10.1093/bjs/znad215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。